Table 1.

Taiho's molecular-targeting early-stage pipeline

Product	Target	Stage	Profile
TAS-115	Met/VEGFR	Phase I	Dual inhibitor of HGF/VEGF signaling
TAS-116	Hsp90α/β	Preclinical	Unique mode of binding with Hsp90α/β; Favorable tissue distribution and minimized ocular toxicity
TAS-117	Akt	Preclinical	Highly potent and selective Akt inhibitor
TAS-2104	Aurora A	Late Preclinical	Highly potent and selective for Aurora A; Enhanced antitumor activity of taxanes
TAS-2913	EGFR T790M	Preclinical	Mutant selective EGFR inhibitor
TAS-2985	FGFR	Preclinical	Highly potent, irreversible FGFR inhibitor

VEGFR, vascular endothelial growth factor receptor; EGFR, epidermal growth factor receptor; FGFR, fibroblast growth factor receptor; HGF, hepatocyte growth factor; VEGF, vascular endothelial growth factor.